The Metabolomics Core for the Undiagnosed Disease Network (UDN) is a partnership between investigators from Pacific Northwest National Laboratory (PNNL) and Oregon Health & Science University (OHSU) . This partnership leverages the advanced mass spectrometry-based metabolomics, lipidomics, and glycomics capabilities available at PNNL, with the expertise in genetics, inherited metabolic disease, and deep semantic phenotyping of the OHSU team, to provide state-of-the-art metabolomics support to the UDN. The Metabolomics Core is led by Co-Principal Investigators Thomas Metz PhD (PNNL), and David Koeller MD (OHSU).
The UDN Metabolomics Core offers a comprehensive array of analyses, including quantitative targeted and untargeted measurements, as well as structural determination of novel metabolites, which can be combined to generate a unique molecular profile for each patient being evaluated. In addition, the metabolomics core works closely with the UDN Clinical Sites to integrate metabolomic and genomic data with clinical signs and symptoms, in order to generate hypotheses regarding pathophysiology that can be translated into specific clues regarding the etiology of the undiagnosed disorders being evaluated.
OHSU team receives $1.8M grant to support mystery diseases research
Portland Business Journal
OHSU-PNNL collaboration selected as Metabolomics Core supporting NIH Undiagnosed Diseases Network
Oregon Health & Science University School of Medicine